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ABSTRACT
Background. Hyperphosphataemia is an independent risk fac-
tor for accelerated cardiovascular disease in chronic kidney dis-
ease (CKD), although the mechanism for this is poorly under-
stood. We investigated the effects of sustained exposure to a
high-phosphate environment on endothelial function in cellular
and preclinical models, as well as in human subjects.
Methods. Resistance vessels from rats and humans (6 CKD)
were incubated in a normal (1.18 mM) or high (2.5 mM) phos-
phate concentration solution and cells were cultured in normal-
(0.5 mM) or high-phosphate (3 mM) concentration media. A
single-blind crossover study was performed in healthy volun-
teers, receiving phosphate supplements or a phosphate binder
(lanthanum), and endothelial function measured was by ﬂow-
mediated dilatation.
Results. Endothelium-dependent vasodilatation was impaired
when resistance vessels were exposed to high phosphate; this
could be reversed in the presence of a phosphodiesterase-5-
inhibitor. Vessels from patients with CKD relaxed normally
when incubated in normal-phosphate conditions, suggesting
that the detrimental effects of phosphate may be reversible.
Exposure to high-phosphate disrupted the whole nitric oxide
pathway with reduced nitric oxide and cyclic guanosine mono-
phosphate production and total and phospho endothelial nitric
oxide synthase expression. In humans, endothelial function was
reduced by chronic phosphate loading independent of serum
phosphate, but was associated with higher urinary phosphate
excretion and serum ﬁbroblast growth factor 23.
Conclusions. These directly detrimental effects of phosphate,
independent of other factors in the uraemic environment, may
explain the increased cardiovascular risk associated with phos-
phate in CKD.
Keywords: cardiovascular risk, chronic kidney disease, endo-
thelial function, nitric oxide, phosphate
INTRODUCTION
Hyperphosphataemia is an independent risk factor for acceler-
ated cardiovascular disease (CVD) in chronic kidney disease
(CKD) [1–7]. CVD is more prevalent in CKD patients than in
the general population and is the biggest single contributor to
markedly reduced life expectancy, with a predominance of sud-
den death and heart failure, rather than coronary artery disease
[8–10]. The relationship between conventional CV risk factors
and CV events in CKD has proved difficult to define and focus
has turned to non-traditional risk factors and therapeutic tar-
gets, such as hyperphosphataemia [5, 11–14]. Based on observa-
tional data linking elevated phosphate with adverse outcomes,
most patients with advanced CKD receive phosphate-lowering
treatment with oral phosphate binders, although we lack spe-
cific evidence on the cardiac and survival benefit of this thera-
peutic strategy [4, 6, 15–23]. There is also strong evidence that
‘normal’ phosphate levels at the upper limit of the reference
range increase the CV risk in other populations, including
recipients of a renal transplant, healthy individuals or individu-
als without CKD but with pre-existing CV disease [12, 14, 22,
24]. One explanation may be that serum phosphate is a poor
measure of total body phosphate, as phosphate is largely an
intracellular anion. This is reflected in CKD, where the CV risk
is increased before phosphate levels rise above the reference
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|range—phosphate seems to be a continuous risk factor,
although a phosphate level within the reference range is largely
ignored in CKD [15].
Phosphate levels can be easily manipulated. Current means
of modification may be suboptimal in terms of risk reduction
and because there is limited information about phosphate’s
mechanism of action as a CV risk factor, it has proved difficult
to determine the best approach to altering phosphate levels
[25]. The established view is that elevated phosphate contributes
to vascular calcification and thus CVD [26–28]. However, alter-
native mechanisms include direct effects of phosphate on endo-
thelial function, and effects mediated by regulators of
phosphate homoeostasis, including fibroblast growth factor 23
(FGF-23), a phosphaturic hormone implicated in cardiac
hypertrophy, another common feature of CKD [4, 28–31]. In
reality it is likely to be a combination of these effects that con-
tributes to CV risk in CKD. Defining the isolated actions of ele-
vated phosphate independent of other abnormalities of the
uraemic environment is challenging.
Emerging evidence supports direct effects of phosphate on
vascular function. Shuto et al. demonstrated impaired endothelial
dysfunction in healthy males following a single high-phosphate
content meal, consistent with an acute effect of phosphate [32].
In the same study, endothelium-dependent vasodilatation was
impaired in rat aortic rings exposed acutely to high-phosphate
concentration. In a preclinical rat model of adenine-induced
CKD, aortic rings from rats fed a low-phosphate diet for 16 days
exhibited significantly improved endothelium-dependent vasodi-
latation compared with animals fed standard rat chow [28]. In
cells in culture, there is evidence of disruption of the nitric oxide
(NO) pathway upon exposure to both a low- and high-phosphate
environment, although the authors attributed this to the concom-
itant reduction in intracellular calcium [33].
Overall, these elegant studies support direct, acute effects of
phosphate on vascular cells and function but they do not
explore more chronic effects that are relevant to CKD, nor the
mechanisms or potential for new therapeutic approaches.
Endothelial dysfunction is a feature of CKD and may con-
tribute to CV risk, probably via disruption of the NO pathway
[32, 34, 35]. We hypothesized that phosphate has direct effects
on endothelial function via dysregulation of the NO pathway
and this explains the association between phosphate and CV
risk. We show, for the first time, in translational cell to animal
to human studies, the direct effects of prolonged exposure to
elevated phosphate concentration on vascular and endothelial
function, specifically examining the isolated actions of elevated
phosphate independent of other effects of the uraemic
environment.
MATERIALS AND METHODS
For detailed materials and methods, see Supplementary
Methods online.
Vessel studies
Rat mesenteric vessels were utilized and human resistance
vessels came from subcutaneous abdominal fat, removed prior
to the use of diathermy or the harmonic scalpel, at the begin-
ning of surgery. Twelve-week-old male Wistar-Kyoto rats were
sacrificed in accordance with the Animals Scientific Procedures
Act 1986. Live kidney donors (LKDs) undergoing nephrectomy
for living kidney donation and patients with CKD undergoing
live donor renal transplant were identified. Blood samples were
collected the day prior to surgery. All myography experiments
were performed on a four-chamber wire myograph.
Experiments were conducted after storage of the vessels at 4C
in a normal- (1.18 mM) or high-phosphate (2.5 mM) concen-
tration solution for 16 h (Supplementary data, Table S1).
Statistical analysis. All responses are expressed as mean 6
standard error of the mean (SEM) and comparison made
between the areas under the curve (AUC) of groups with
Student’s t test, unless otherwise stated. For comparisons
between maximal vasodilation or contractile responses, an
unpaired Student’s t test (rat vessels) or an ANOVA with
Tukey’s post hoc analysis (human vessels) was used. The median
L100 (rat vessels only) and the median vessel lengths were com-
pared with a Mann–Whitney U test. Statistical analysis was per-
formed in SPSS v 19 (IBM, Armonk, NY, USA).
Cell culture
Cell media was either of standard phosphate concentration
(0.5 mM) or custom formulated (phosphate concentration 3
mM). Cells were grown in standard phosphate concentration
medium until they reached 90% confluence. At the first passage,
they were divided into standard and high-phosphate concentra-
tion cells and grown in the appropriate media from that point.
Clinical study
This was a single-blind crossover study with healthy volun-
teers without CKD. Volunteers were screened to ensure they
were ‘healthy’ prior to inclusion. Each participant attended
three visits. At visit one, patients were randomized to receive
either 500 mg phosphate or 1000 mg of lanthanum three times
daily for 2 weeks. The participants knew which tablet they were
taking but the investigator did not. After 2 weeks, patients
attended for the second visit. After a further 2-week washout
period, patients received the other drug for 2 weeks, before
attending for the final visit. Supplementary data, Figure S1 illus-
trates the study visit protocol. At each visit, the same measures
were taken and pill counts were performed to assess
compliance.
Serum and plasma samples were sent to the laboratory and
blood was stored at80C for FGF-23, cyclic guanosine mono-
phosphate (cGMP) and vitamin D analysis. Prior to each visit, a
24 h urine collection was obtained.
Endothelial function was measured using flow-mediated
dilatation (FMD) and measurements were standardized [36].
All recordings and analyses were performed by one investigator.
Vascular stiffness was measured using the SphygmoCorVR Vx
system and standardized [37].
Statistical analysis. Data were assessed for normality.
Univariate and multivariate linear regression models were con-
structed with change in FMD from baseline as the measure of
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|outcome. The crossover nature of the study utilizing the same
patients for each arm was taken into account and randomiza-
tion order was included in the model. One-third of the images
were randomly selected and reanalysed to test reproducibility
and intra-observer variability.
RESULTS
We exposed cells and vessels to two phosphate concentrations,
normal and high (0.5 and 3 mM in cell lines and 1.18 and
2.5 mM in vessels). For context, 0.5 mM is the standard concen-
tration of phosphate in the conventional cell culture medium
suited to the cells utilized, 0.8–1.4 mM is the normal plasma
range in humans, whilst 2.5–3 mM is at the extreme of the CKD
spectrum.
Effect of phosphate on the function of rat and human
vessels in vitro
Table 1 shows the numbers of rat mesenteric vessels used
and their normalized internal diameter (L100), which was not
significantly different between the groups. In phenylephrine
(PEP) pre-constricted vessels, the endothelium-dependent vas-
odilator carbachol was less effective in high- compared with
normal-phosphate conditions (Figure 1A; maximum vasodila-
tation 646 9% versus 956 1%; P < 0.001). When we assessed
basal NO production using the NO synthase inhibitor L-NAME
(LN), we found that in normal-phosphate vessels, LN shifted
the concentration–response curve to PEP significantly to the
left compared with contraction in the absence of LN
(Figure 1B). In high-phosphate conditions, no significant shift
was observed (EC50 þ LN: 4.5 6 2.1  106 M versus EC50-
LN: 5.3 6 2.8  106 M; data not shown). To assess
endothelium-independent vasodilatation, we used the NO
donor sodium nitroprusside (SNP). Vasodilatation to SNP was
reduced in high- versus normal-phosphate conditions
(Figure 1C; maximal vasodilatation 45 6 22% versus 73 6 26;
P ¼ 0.02). Adding zaprinast, a phosphodiesterase (PDE5)
inhibitor (1  105 M for 1 h), to increase levels of cGMP
reversed the effects of high phosphate, improving vasodilator
responses to carbachol and SNP (Figure 1D and E).
These data are consistent with impaired endothelium-
dependent and -independent vasodilation and reduced basal
NO production in high-phosphate conditions, effects that are
potentially reversible.
To determine whether these findings could be translated to
humans, we studied resistance vessels from LKDs and patients
with CKD stage 5 (Table 2). Vessels were obtained at the time of
live donor nephrectomy or at the time of transplantation.
Comparisons were made between subjects with and without
CKD. The former had higher serum phosphate and FGF-23 lev-
els. Eighty-nine per cent (n ¼ 8) received a phosphate binder.
No patient was taking drugs that interfere with NOmetabolism.
Table 3 details the vessels used.
In LKD vessels, in high-phosphate compared with normal-
phosphate conditions, vasodilatation to carbachol was impaired
(Figure 2A; maximum vasodilatation 42.96 12% versus 79.46
8.2%; P ¼ 0.003). Similarly, high-phosphate LKD vessels vaso-
dilated less well to SNP compared with normal-phosphate ves-
sels (Figure 2B; maximum vasodilatation 59.7 6 13.8% versus
99.86 20.2%; P ¼ 0.02). Impaired vasodilation with carbachol
was also observed in CKD vessels incubated in high- versus
normal-phosphate conditions (Figure 2C; maximum vasodila-
tation 25.36 11.1% versus 75.76 13.6%; P< 0.001).
Interestingly, there was no significant difference in either
AUC or maximal relaxation between the CKD and the LKD
vessels incubated in normal-phosphate conditions, supporting
the notion that the effects of phosphate may be reversible.
There was no significant difference in relaxation to SNP
between the CKD vessels incubated in high- or normal-
phosphate conditions (Figure 2D). In LKD with normal renal
function, both endothelium-dependent and -independent
Table 1. Comparison of numbers of vessels studied for each drug and the corresponding size of the vessels
Incubated in standard phosphate Incubated in high phosphate P
Phenylephrine
Number 12 10
L100 366.5 (292.7–422.3) 401.6 (226.3–525.4) NS
Carbachol
Number 12 10
L100 366.5 (292.7–422.3) 401.6 (226.3–525.4) NS
L-Name
Number 12 10
L100 366.5 (292.7–422.3) 401.6 (226.3–525.4) NS
SNP
Number 11 9
L100 391.9 (311.2–504.3) 396.9 (267.5–525.3) NS
Carbachol and PDE5I
Number 10 13
L100 387.2 (324.2–412.1) 384.1 (341–411.6) NS
SNP and PDE5I
Number 10 13
L100 387.2 (324.2–412.1) 384.1 (341–411.6) NS
Number is the number of vessels for which a complete concentration response curve was obtained. L100 is the normalized internal diameter of the vessels with comparison by the
Mann–Whitney U test.
PDE5I, phosphodiesterase-5 inhibitor (zaprinast); SNP, sodium nitroprusside; NS, not signiﬁcant.
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||vasodilation are impaired, consistent with the effects observed
in our preclinical model. In CKD resistance vessels
endothelium-dependent vasodilation was blunted in high-
phosphate conditions, but when incubated ex vivo in a normal-
phosphate solution, the relaxation response was similar to that
of healthy LKD vessels.
Effect of phosphate on the NO pathway
Since the data above, in isolated vessels, suggest a direct and
reversible effect of phosphate on the endothelium mediated by
disruption of both basal and stimulated NO production, we
next explored the NO pathway further by examining the effects
of phosphate in cell lines.
FIGURE 1: Rat mesenteric vessels incubated in a high-phosphate concentration (2.5 mM) solution have impaired endothelium-dependent and
-independent vasodilatation, an effect that can be reversed when the vessels are co-incubated with a phosphodiesterase-5 inhibitor (PDE5I),
zaprinast. Vessels were incubated for 16 h in either a normal (1.18 mM) or high (2.5 mM) phosphate concentration solution and all responses
are expressed as mean6 SEM. (A and C) Vasodilatation to increasing concentrations of carbachol or SNP, respectively, expressed as a % of
maximal contraction with PEP 1  105 M. (B) Contraction with PEP in the presence and absence of L-NAME. (D and E) Vasodilatation to
increasing concentrations of carbachol or SNP, respectively, in the presence of zaprinast (PDE5I) expressed as a % of maximal contraction with
PEP 1  105 M. n ¼ 10–13 vessels (see Table 1).
Table 2. Demographics of the study population
Parameter Live donor CKD P
Age (years) 48.86 10.2 44.66 14.5 NS
Male sex (%) 64 44
Systolic BP 1346 16 1346 24 NS
BMI 29.56 3.6 25.46 3.4 0.02
Dialysis (%) 0 44
eGFR (mL/min/1.73 m2) 95.86 21 8.06 3.0 <0.001
Phosphate (mmol/L) 1.16 0.1 1.76 0.6 0.003
Adjusted calcium (mmol/L) 2.46 0.1 2.56 0.1 NS
FGF-23 (RU/mL) 45.8 (40.5–51.7) 1644 (1135.7–1750.4) <0.001
On any medication (%) 18 100
Calcium-containing phosphate binder (%) 0 33
Non-calcium-containing phosphate binder (%) 0 67
Alfacalcidol (%) 0 78
Cinacalcet (%) 0 0
Antihypertensive (%) 18 89
BP, blood pressure; BMI, body mass index; NS, not signiﬁcant.
Live donor, vessels from live donor nephrectomy; CKD, vessels from recipients of live kidney transplant. Demographics for the patients whose vessels were used are shown in columns
two to four. Live donor, n ¼ 14 and CKD, n ¼ 14.
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Table 3. Comparison of numbers of vessels studied for each patient group
CKD Live donor
Normal High Normal High
Length 4.766 0.36 4.526 0.49 4.596 0.35 4.51 6 0.44
Diameter 494.3 (339–700) 460.9 (340–792) 534.2 (286–879) 438.4 (297–684)
Phenylephrinea 12 9 13 12
Carbachola 12 9 11 12
SNPa 12 9 13 12
Measurements are in microns.
The number of vessels in which a complete concentration response curve was obtained for each drug and the corresponding size of the vessels are presented. Comparison was made
with a one-way ANOVA.
aThese values represent the number of vessels used (n).
FIGURE 2: Human resistance vessels from patients with (C) and without (A) CKD incubated in a high-phosphate concentration (2.5 mM)
solution have impaired endothelium-dependent vasodilatation. Endothelium-independent vasodilatation is impaired in vessels from humans
without CKD (B) but preserved in those with CKD (D). Vessels were incubated for 16 h in either a normal (1.18 mM) or high (2.5 mM)
phosphate concentration solution and all responses are expressed as mean 6 SEM. (A and C) Vasodilatation to increasing concentrations of
carbachol expressed as a % of contraction with PEP 1  105 M in vessels from living kidney donors without CKD (A) and from patients with
CKD stage 5 (C). (B and D) Vasodilatation to increasing concentrations of SNP expressed as a % of contraction with PEP 1  105 M in vessels
from living kidney donors without CKD (B) and from patients with CKD stage 5 (D). n ¼ 9–14 vessels (see Table 3).
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|We measured endothelial nitric oxide synthase (eNOS)
expression and NO production in human umbilical vein endo-
thelial cells (HUVECs), as well as nitrotyrosine expression to
investigate the role of reactive oxygen species (ROS) and free
radicals in the high-phosphate environment. Total and phospho
eNOS (normalized to GAPDH) and NO levels (data not shown)
were significantly reduced in HUVECs cultured in high-
phosphate conditions (Figure 3A and B). There was evidence of
increased free radical formation in a high-phosphate environ-
ment as there was increased expression of nitrotyrosine
(Figure 3C).
The smooth muscle cell is vital for a contractile response
instigated via an intact NO pathway. In view of the impaired
endothelium-independent vasodilatation to SNP observed in
our resistance vessels, we measured cGMP levels in vascular
smooth muscle cells and the resistance vessels exposed to nor-
mal and high-phosphate environments and protein kinase G
(PKG), a cGMP-dependent kinase implicated in the relaxation
of smoothmuscle.
In rat vascular smooth muscle cells (VSMCs), cultured in
high-phosphate conditions, PKG expression was significantly
reduced (Figure 3D). In rat mesenteric vessels, cGMP was
FIGURE 3: HUVECs express reduced total (A) and phospho (B) eNOS and increased nitrotyrosine (C) when cultured in high-phosphate
concentration medium (3 mM). PKG expression is reduced in rat VSMCs cultured in high- compared with normal-phosphate concentration
medium. **P < 0.05. HUVECs and VSMCs were cultured in 0.5 mM or 3 mM phosphate concentration medium. Ten mg of protein was
fractionated on SDS page gels. Primary antibodies for Total eNOS (1:1000), Phospho eNOS (1:200) (both Cell Signalling Technology), nitrotyr-
osine (1:500, R & D Systems), PKG (1:200, Enzo Life Sciences) and protein expression normalized to GAPDH. Densitometry was performed.
In (A)–(D), top panels show representative gel from cells cultured in 0.5 or 3 mM phosphate concentration medium and bottom panels show
GAPDH. The panels were all taken from a single gel and each band represents one well from separate six-well plates.
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higher in vessels incubated in low- versus high-phosphate con-
ditions (715.6(418–1541) pM/mg versus 330.6 (284.1–500.1)
pM/mg; P ¼ 0.0026; Figure 4A). In a high-phosphate environ-
ment, in support of our hypothesis that there is disruption in
the entire NO pathway from the endothelial cell to the smooth
muscle cell, we demonstrate reduced eNOS and PKG and
increased nitrotyrosine expression, and reduced NO and cGMP
production.
Although these data are consistent with a direct effect of
phosphate, we measured intracellular calcium to exclude an
indirect effect mediated by reduction in intracellular calcium. In
HUVECs, intracellular calcium measurements were not signifi-
cantly different between cells cultured in high- versus normal-
phosphate conditions (Figure 4B; 749.5 6 13.9 nM versus 752
6 54.2 nM; P ¼ not significant); rat VSMCs showed the same
pattern (228.36 22.0 nM versus 2786 22.4 nM).
Effects of sustained phosphate loading in healthy human
volunteers
To determine whether the observations on NO and endothe-
lial function in cellular and preclinical models are of physiologi-
cal relevance in man, we performed a study of phosphate
loading and phosphate binders (lanthanum) in healthy subjects,
using FMD to assess endothelial function. Healthy volunteers,
rather than CKD patients, were selected initially to allow study
of the sole effects of phosphate, independent of the uraemic
milieu.
Table 4. Participant demographics at baseline, following lanthanum and phosphate
Parameter Baseline Post-lanthanum Post-phosphate P-value
Age (years) 42.26 14.3
Male sex 36.8% (n ¼ 7)
BMI 26.06 4.1 26.36 3.9 26.36 3.8 NS
Creatinine (mM) 66.46 6.3 65.86 6.8 65.86 6.6 NS
Systolic BP (mmHg) 123.16 15.8 122.96 10.3 119.86 16.8 NS
Diastolic BP (mmHg) 74.56 10.5 75.26 9.4 74.16 12.1 NS
Adjusted calcium (mmol/L) 2.356 0.07 2.366 0.05 2.346 0.09 NS
Phosphate (mmol/L) 1.056 0.18 1.036 0.18 1.066 0.16 NS
Vitamin D3 (nmol/L) 48.26 23.3 40.36 20.6 45.66 25.8 NS
PTH (pg/mL) 5.96 2.1 5.86 1.4 6.46 2.3 NS
FGF-23 (RU/mL) 49.7 (45.9–69.1) 59.1 (38.2–73.4) 66.6 (50.0–84.9) 0.028
FGF-23% change 21 (219.8–21.7) 19.6 (3.1–38.9) 0.004
FeP (%) 14.36 3.4 11.46 4.3 28.46 9.2 <0.001
Urinary phosphate (mmol/day) 28.46 14.7 23.26 12.3 54.96 19.2 <0.001
Urinary cGMP (nmol/L) 472.8 (312–645.4) 530.6 (288.2–756.4 501.1 (274.9–674.0) NS
Urinary FGF-23 (RU/mL) 46.1 (26.6–288.2) 139.5 (31.3–360.6) 227.9 (39.4–405.8) NS
FMD post-cuff (%) 8.4 (6.2–11.6) 6.6 (3.4–10.3) 3.4 (2.6–5.3) <0.001
FMD post-cuff % change 223.5 (259 to a^ 0.2) 258.1 (271.9 to a^ 43.4) <0.001
FMD post-GTN (%) 17.7 (13.4–23.2) 17.2 (12.3–23.7) 16.3 (12.1–17.7) NS
PWV (m/s) 7.46 1.9 7.36 1.7 7.16 1.6 NS
AI@75 12.86 12 12.56 13.1 9.96 12.6 NS
BMI, body mass index; BP, blood pressure; PTH, parathyroid hormone; FeP, fractional excretion of urinary phosphate; FMD, ﬂow-mediated dilatation; PWV, pulse wave velocity;
AI@75, aortic augmentation index corrected to a heart rate of 75 beats per minute; NS, not signiﬁcant. P-value is in comparison with baseline values.
Statistically signiﬁcant differences (P < 0.05) between baseline and subsequent measures are indicated in bold. % change refers to the % change in a particular parameter when com-
pared with the value obtained at baseline.
FIGURE 4: cGMP concentration is signiﬁcantly reduced in rat vessels incubated for 24 h in a high-phosphate concentration solution (A),
whereas the intracellular calcium level in HUVECs is unchanged in a high-phosphate environment (B). (A) Rat mesenteric resistance vessels
were incubated in a 1.18 mM (n ¼ 11) or 2.5 mM (n ¼ 11) phosphate concentration solution for 24 h. Results are expressed as cGMP pM/mg
protein. Analysis was by the Mann–Whitney U test. (B) Cells were plated in glass-bottomed plates and cytosolic loading of FURA-2-AM was
achieved by incubating the cells with FURA-2-AM. Values are mean 6 SEM and are from at least four experiments with the number of cells
included indicated by (n).
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|We recruited 19 volunteers: 63% (n ¼ 12) were female and
the mean age was 42.26 14.3 years (Table 4). At baseline, mean
estimated glomerular filtration rate (eGFR) was 102 6 10 mL/
min/1.73 m2, serum phosphate level was 1.05 6 0.18 mmol/L
and the fractional excretion of urinary phosphate (FeP) was
14.3 6 3.4%. Participants were normoglycaemic, with normal
mean lipid values. The median FMD was 8.4% (6.2–11.6%)
post-cuff inflation and 17.7% (13.4–23.2%) post-GTN spray.
Table 4 shows the effect of each intervention. Phosphate sup-
plementation was associated with a significant reduction in
FMD [Figure 5; 3.4% (2.6–5.3%); P < 0.001]. With lanthanum,
FMD also fell [Figure 5; 6.6% (3.4–10.3%); P ¼ 0.033]. Post-
GTN, as expected, there was significant increase in vessel diam-
eter but there was no significant effect of phosphate supplemen-
tation or binding on GTN-mediated dilatation; randomization
order was not a predictor of either FMD or GTN-mediated dila-
tation. In univariate analyses, the change in the serum phos-
phate level from baseline, change in serum FGF-23 from
baseline and FeP were significant predictors of FMD. In a multi-
ple regression model (Table 5), the inclusion of serum FGF-23
and urinary FeP was significantly associated with the change in
FMD from baseline [F(2,54) ¼ 10.1; P < 0.001; r2 ¼ 0.28].
Inclusion of systolic blood pressure, serum phosphate, age, sex,
urinary FGF-23, urinary calcium or urinary cGMP levels did
not increase the amount of variation of change in FMD
explained by the model. By recoding the three drug categories
(no drug, lanthanum, phosphate), we included effects of lantha-
num and oral phosphate in a multivariate model with the
change in FMD as a % of the baseline visit as the dependent var-
iable. The change in FeP and that in serum FGF-23 were
included as covariates, resulting in an improved model [F(4,52)
¼ 18.3; P< 0.001; r2¼ 0.59].
Urinary cGMP were measured as a marker of endothelial
function, and correlated inversely with FeP, consistent with dis-
ruption of the NO pathway (r ¼ 0.39; P 0.003). In univariate
analysis, serum phosphate, age, male sex and FeP were associ-
ated with urinary cGMP levels. Overall, at the end of the treat-
ment phases of phosphate supplementation and lanthanum
treatment, there was no significant difference in mean serum
phosphate, parathyroid hormone (PTH), vitamin D, adjusted
calcium or magnesium levels compared with baseline visit val-
ues. Serum FGF-23 levels increased significantly following
phosphate supplementation and fell, albeit not significantly, fol-
lowing lanthanum, compared with baseline.
DISCUSSION
This paper investigates the independent, direct actions of phos-
phate in cells, vessels and human subjects, in order to understand
the potential effects of phosphate as a CV risk factor. The prevail-
ing view has been that elevated serum phosphate increases CV
risk by promoting vascular calcification, and more recently that
increased levels of FGF-23 contribute to CV risk by promoting
cardiac hypertrophy. Our data provide strong support for an
additional direct effect of phosphate resulting in endothelial dys-
function, mediated via disruption of the NO pathway.
Direct actions of phosphate and the NO pathway
The ex vivo studies demonstrate that sustained exposure to
phosphate, independent of other features of the uraemic envi-
ronment, causes impaired endothelium-dependent vasodilata-
tion in resistance vessels. This supports a direct detrimental
effect of phosphate, and this appears to be mediated by NO,
with evidence of reduced basal and stimulated NO production.
Endothelium-independent vasodilation is also impaired in rat
and human LKD vessels exposed to high-phosphate concentra-
tion, suggesting disruption of the whole NO pathway. Adding
zaprinast improved both endothelium-dependent and inde-
pendent vasodilatation in vessels incubated in high-phosphate
conditions. Zaprinast inhibits cGMP breakdown, increasing
cGMP levels, and is beneficial in pulmonary hypertension
where endothelial dysfunction is present [38, 39]. This could be
a potential therapeutic option.
Our cellular models support the concept of disruption to the
NO pathway with reduced basal NO, reduced expression of
phosphorylated and total eNOS and PKG, lower concentrations
of cGMP and increased nitrotyrosine expression. Some of these
effects may be reversible. The finding that CKD vessels incu-
bated in normal-phosphate conditions relaxed as well as LKD
vessels did, with carbachol is consistent with a degree of adapt-
ability and reversibility of the effects of phosphate in CKD.
Actions of phosphate in the uraemic environment
In CKD vessels, endothelium-dependent relaxation was
impaired, but only with incubation in a high-phosphate envi-
ronment. In a normal-phosphate environment, CKD vessels
relax as well as LKD vessels. Unlike the LKD and rat vessels,
endothelium-independent relaxation did not appear to be
impaired in CKD.
FIGURE 5: Change in FMD from baseline visit measures, following
intervention with lanthanum and phosphate expressed as a % change
from the baseline visit.
Table 5. Multiple regression model with post-cuff FMD as the outcome
measure
Variable B Confidence interval P-value
Lower bound Upper bound
FeP 1.1 1.9 0.2 0.014
Serum FGF-23 0.5 0.7 0.2 0.002
Urinary phosphate and serum FGF-23 are signiﬁcant predictors of post-cuff FMD.
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|These findings may reflect adaptive changes during chronic
exposure to high-phosphate concentration in the uraemic envi-
ronment, altering the responses to subsequent changes in phos-
phate. Our results conflict with a previous study from our group
in human uraemic resistance vessels that showed impaired
endothelium-dependent and, to a lesser extent, independent
function in CKD [40]. In the present study, CKD vessels
showed endothelial dysfunction, compared with normal vessels,
with sustained exposure to high-phosphate concentration simi-
lar to uraemic levels. In contrast, the study of Morris et al. used
no added phosphate [40]. It is likely that the effects of extracel-
lular phosphate are mediated via changes in intracellular phos-
phate, which will equilibrate with time. Removing vessels from
a CKD environment will also ‘wash out’ circulating factors,
which may include asymmetric dimethylarginine and ROS [41,
42]. Phosphate itself might cause increased ROS, given that
nitrotyrosine (a product of tyrosine nitration mediated by ROS)
was increased in cells cultured in high-phosphate conditions.
The timing of such effects and the timescale of their reversibility
is unclear and requires further study.
Physiological relevance in humans
In vivo, we have shown similar effects to the in vitro studies:
sustained oral phosphate loading causes endothelial
dysfunction. Serum phosphate is <1% of total body phosphate
and did not change significantly during treatment. The serum
FGF-23 level rose by around 20% during phosphate loading
and urinary phosphate excretion by 50% compared with base-
line. This suggests that compliance with study medication dem-
onstrates phosphate homoeostasis and highlights the
limitations of serum phosphate as a measure of total body phos-
phate. In early CKD, serum phosphate is maintained within the
reference range and rises consistently only when eGFR drops
below 30 mL/min/1.73 m2, although in population studies,
serum phosphate—even within the ‘normal’ range—is linked to
CV risk. It may be that serum phosphate is an insensitive,
homoeostatically regulated marker of total body phosphate
which, in turn, influences endothelial function. A more precise
estimate of risk may be derived from serum phosphate, FGF-23
levels and urinary phosphate levels—accounting for phosphate
intake and total body excess. This is supported by our findings
associating elevated serum FGF-23 and urinary phosphate
excretion with poorer endothelial function. FeP is likely to be a
better indicator of actual phosphate leak per nephron than
standard 24 h urinary phosphate, by accounting for serum
phosphate levels [43]. In the clinical setting, it may be possible
to use a phosphate:creatinine ratio or a spot FeP to provide
additional information about phosphate intake and activation
FIGURE 6: Possible mechanism of action of phosphate as a cardiovascular risk factor causing both a pro-inﬂammatory state and endothelial
dysfunction. Using evidence presented in this manuscript and previous studies, we propose this as the possible mechanism of action of
phosphate resulting in endothelial dysfunction and a pro-inﬂammatory state. Additionally, we have some evidence of an effect of phosphate
on cell growth (data not yet published).
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of phosphaturic mechanisms. Whether such detail has any clin-
ical benefit would need to be investigated in a clinical trial.
Several small studies have demonstrated an association between
FGF-23 and dietary phosphate intake in healthy volunteers with
increased phosphate intake over a few days resulting in
increased levels of serum FGF-23 [44, 45]. Increased levels of
FGF-23 correlate with increased serum phosphate, urinary
excretion of phosphate and vitamin D levels [44]. Urinary phos-
phate excretion alone or in combination with measures of FGF-
23 may be a better surrogate for total body phosphate than the
serum phosphate level.
CKD patients may respond differently to sustained phos-
phate loading and thus results from our clinical study cannot be
extrapolated to the CKD population. Our study was not pow-
ered to assess the direct effects of either phosphate supplemen-
tation or lanthanum and so no firm conclusions about
lanthanum and endothelial function can be drawn. We chose
lanthanum as a non-calcium-containing ‘single tablet’ binder,
without well-described effects on confounding factors, for
example the lipid-lowering properties of sevelamer [18].
Further studies on the direct effects of lanthanum on vascular
function, and comparison of different classes of binder or diet,
are merited.
Naturally, there are limitations of our work. We deliberately
used the extreme ends of the phosphate spectrum (not least
because standard concentration medium contains 0.5 mM
phosphate), but dose response experiments using concentra-
tions of phosphate in between 0.5 mM and 3 mM would be of
value. We acknowledge that our findings are likely to form only
part of the explanation for the increased CV risk associated with
phosphate and it seems probable that vascular calcification and
FGF-23 and PTH also play a role. However, to help tease out
the isolated effects of phosphate, we deliberately chose to study
it alone and not look at effects of its key regulators, i.e. FGF-23
and PTH in vivo and in vitro. Similarly, this is why we used
healthy volunteers for our clinical study.
In conclusion, these studies show that phosphate has directly
detrimental effects on the endothelium and vasculature, effects
that are likely to be mediated by disruption of the whole NO
pathway (Figure 6). Some of the effects may be reversible, either
by manipulation of phosphate or pharmacologically, for exam-
ple by inhibiting PDE5 (Figure 6). We have previously shown
direct effects of phosphate on inflammation, leading to a pro-
inflammatory state [46].
The clinical study presented here shows that the in vitro
effects are of functional relevance and likely to play a role in the
CV risk associated with high-phosphate concentration. It is our
impression that intracellular, rather than extracellular phosphate
is central to the observed effects. Drugs which inhibit cellular
phosphate uptake may offer an alternative strategy to target
adverse effects of hyperphosphataemia in CKD. Future work
should consider the measurement of intracellular phosphate.
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